News
Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.
More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...
Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, discusses the importance ...
More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...
India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...
Significant periods of weight regain were observed at eight, 12, and 20 weeks after stopping the anti-obesity medications.
While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...
Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...
Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...
Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results